To CURE META-static disease by targeting embryonic-like cancer stem cells


CureMeta is a privately funded cancer research biotech company located in the Seaport district of Boston Massachusetts. Our research efforts at CureMeta - which stands for curing metastatic cancer - are focused on developing novel cancer diagnostic tests and new therapeutic cancer drugs. CureMeta’s overall goals are to develop methods to identify aggressive cancers and to reduce misdiagnosis/over treatment of non aggressive/indolent abnormal tissues found in organs such as prostate and breast, and to develop new drugs to destroy the aggressive cancer stem cells which drive the metastatic process and are the underlying basis of cancer recurrence and resistance after conventional cancer treatments.